ArticleJournal of magnetic resonance imaging : JMRI2026
Fat-Corrected Non-Gaussian Diffusion MRI for Liver Fibrosis Assessment in Metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in Journal of magnetic resonance imaging : JMRI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Imaging of MASLD: clinical standards and novel methods.Diabetologia · 2026Review
- Fat-Corrected Non-Gaussian Diffusion MRI for Liver Fibrosis Assessment in Metabolic Dysfunction-Associated Steatotic Liver Disease.Journal of magnetic resonance imaging : JMRI · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIn patients with metabolic dysfunction-associated steatotic liver disease (MASLD), non-Gaussian diffusion-weighted imaging (DWI) has been proposed for the diagnosis of liver fibrosis, but its measurement is partially confounded by steatosis. We therefore asked whether a fat-corrected approach could improve fibrosis assessment. PURPOSE: To evaluate the diagnostic performance of non-Gaussian diffusion coefficients for the assessment of fibrosis in MASLD patients with a method accounting for intravoxel fat. STUDY TYPE: Prospective single-center cross-sectional study. POPULATION: A total of 289 participants with Type 2 diabetes, hepatic steatosis, and elevated aminotransferases were enrolled from October 2018 to June 2021. Among them, 222 participants (mean age 59 ± 10 years; 149 men) underwent liver biopsy and MRI and were included in the final analysis. FIELD STRENGTH/SEQUENCE: 3 T, DWI using spin-echo echo-planar imaging, MR elastography (MRE) using gradient echo sequence and fat fraction imaging using a multiple gradient echoes sequence. ASSESSMENT: Diffusion coefficients were estimated using two non-Gaussian models: a shifted apparent diffusion coefficient (sADC) and a non-linear least squares fit (ngADC), both computed without and with intravoxel fat correction (corr) using fat fraction on PDFF. Fibrosis was staged histologically. Quantitative parameters were compared across fibrosis stages. Diagnostic performance for F0 versus ≥ F1 was evaluated and compared to liver stiffness on MRE. STATISTICAL TESTS: Group comparisons used Kruskal-Wallis tests (α = 0.05), and diagnostic performance was assessed via receiver operating characteristic (ROC) curve analysis with 95% confidence intervals, with p < 0.05 considered statistically significant.
resultsngADC DATA
conclusionFit-based non-Gaussian DWI with fat correction could potentially be used with similar diagnostic accuracy as MRE for detecting fibrosis in patients with MASLD. EVIDENCE LEVEL: 3. TECHNICAL EFFICACY: Stage 2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.